Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Othon Iliopoulos, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA215431 (ILIOPOULOS, OTHON) May 1, 2017 - Apr 30, 2022
    NIH
    Chemical Biology of IRP1-HIF2a Signaling
    Role: Principal Investigator
  2. R01CA160458 (ILIOPOULOS, OTHON) Jul 20, 2012 - Apr 30, 2017
    NIH
    Hypoxia-induced Metabolic Changes in Cancer
    Role: Principal Investigator
  3. R01CA122591 (ILIOPOULOS, OTHON) Sep 15, 2008 - Jan 31, 2014
    NIH
    Identification of Biomarkers for Early Detection of Renal Cell Carcinoma
    Role: Principal Investigator
  4. R01CA104574 (ILIOPOULOS, OTHON) Jul 9, 2004 - Apr 30, 2009
    NIH
    Molecular targets of hypoxia in signaling cancer
    Role: Principal Investigator
  5. P50CA101942 (MCDERMOTT, DAVID) Sep 18, 2003 - Aug 31, 2025
    NIH
    DF/HCC Kidney Cancer SPORE
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Arevalo A, Patel N, Muraki P, Ohtake S, Bratslavsky G, Clark C, Mann J, Iliopoulos O, Jonasch E, Srinivasan R, Shuch B. Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL. J Kidney Cancer VHL. 2022; 9(3):41-46. PMID: 36310638; PMCID: PMC9551368.
    Citations:    
  2. Meric-Bernstam F, Tannir NM, Iliopoulos O, Lee RJ, Telli ML, Fan AC, DeMichele A, Haas NB, Patel MR, Harding JJ, Voss MH, Owonikoko TK, Carthon B, Srinivasan R, Bendell JC, Jenkins Y, Whiting SH, Orford K, Bennett MK, Bauer TM. Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. Clin Cancer Res. 2022 04 14; 28(8):1540-1548. PMID: 35140121; PMCID: PMC9164172.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  3. Woodford MR, Andreou A, Baba M, van de Beek I, Di Malta C, Glykofridis I, Grimes H, Henske EP, Iliopoulos O, Kurihara M, Lazor R, Linehan WM, Matsumoto K, Marciniak SJ, Namba Y, Pause A, Rajan N, Ray A, Schmidt LS, Shi W, Steinlein OK, Thierauf J, Zoncu R, Webb A, Mollapour M. Seventh BHD international symposium: recent scientific and clinical advancement. Oncotarget. 2022; 13:173-181. PMID: 35070081; PMCID: PMC8780807.
    Citations:    Fields:    
  4. Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 11 25; 385(22):2036-2046. PMID: 34818478; PMCID: PMC9275515.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  5. Calvo IA, Sharma S, Paulo JA, Gulka AOD, Boeszoermenyi A, Zhang J, Lombana JM, Palmieri CM, Laviolette LA, Arthanari H, Iliopoulos O, Gygi SP, Motamedi M. The fission yeast FLCN/FNIP complex augments TORC1 repression or activation in response to amino acid (AA) availability. iScience. 2021 Nov 19; 24(11):103338. PMID: 34805795; PMCID: PMC8590082.
    Citations:    
  6. Bratslavsky G, Mendhiratta N, Daneshvar M, Brugarolas J, Ball MW, Metwalli A, Nathanson KL, Pierorazio PM, Boris RS, Singer EA, Carlo MI, Daly MB, Henske EP, Hyatt C, Middleton L, Morris G, Jeong A, Narayan V, Rathmell WK, Vaishampayan U, Lee BH, Battle D, Hall MJ, Hafez K, Jewett MAS, Karamboulas C, Pal SK, Hakimi AA, Kutikov A, Iliopoulos O, Linehan WM, Jonasch E, Srinivasan R, Shuch B. Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer. 2021 Nov 01; 127(21):3957-3966. PMID: 34343338; PMCID: PMC8711633.
    Citations:    Fields:    Translation:Humans
  7. Allouche J, Rachmin I, Adhikari K, Pardo LM, Lee JH, McConnell AM, Kato S, Fan S, Kawakami A, Suita Y, Wakamatsu K, Igras V, Zhang J, Navarro PP, Lugo CM, Noonan HR, Christie KA, Itin K, Mujahid N, Lo JA, Won CH, Evans CL, Weng QY, Wang H, Osseiran S, Lovas A, Németh I, Cozzio A, Navarini AA, Hsiao JJ, Nguyen N, Kemény LV, Iliopoulos O, Berking C, Ruzicka T, Gonzalez-José R, Bortolini MC, Canizales-Quinteros S, Acuna-Alonso V, Gallo C, Poletti G, Bedoya G, Rothhammer F, Ito S, Schiaffino MV, Chao LH, Kleinstiver BP, Tishkoff S, Zon LI, Nijsten T, Ruiz-Linares A, Fisher DE, Roider E. NNT mediates redox-dependent pigmentation via a UVB- and MITF-independent mechanism. Cell. 2021 08 05; 184(16):4268-4283.e20. PMID: 34233163; PMCID: PMC8349839.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  8. Keibler MA, Dong W, Korthauer KD, Hosios AM, Moon SJ, Sullivan LB, Liu N, Abbott KL, Arevalo OD, Ho K, Lee J, Phanse AS, Kelleher JK, Iliopoulos O, Coloff JL, Vander Heiden MG, Stephanopoulos G. Differential substrate use in EGF- and oncogenic KRAS-stimulated human mammary epithelial cells. FEBS J. 2021 10; 288(19):5629-5649. PMID: 33811729; PMCID: PMC8487438.
    Citations:    Fields:    Translation:HumansAnimalsCells
  9. Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, Rathmell WK, Daniels AB, Jonasch E, Spiess PE. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol. 2021 Jul; 39(7):2409-2415. PMID: 32936333.
    Citations: 3     Fields:    Translation:HumansPHPublic Health
  10. Madala HR, Helenius IT, Zhou W, Mills E, Zhang Y, Liu Y, Metelo AM, Kelley ML, Punganuru S, Kim KB, Olenchock B, Rhee E, Intlekofer AM, Iliopoulos O, Chouchani E, Yeh JJ. Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction. Cancer Res. 2020 09 01; 80(17):3492-3506. PMID: 32651261.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  11. Dahl DM, Simeone JF, Iliopoulos O, Saylor PJ, Wu CL. Case 36-2018: A 29-Year-Old Man with an Incidentally Discovered Renal Mass. N Engl J Med. 2018 11 22; 379(21):2064-2072. PMID: 30462933.
    Citations:    Fields:    Translation:Humans
  12. Schneider M, Dinkelborg K, Xiao X, Chan-Smutko G, Hruska K, Huang D, Sagar P, Harisinghani M, Iliopoulos O. Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion. Fam Cancer. 2018 01; 17(1):135-139. PMID: 28623476.
    Citations: 5     Fields:    Translation:Humans
  13. Laviolette LA, Mermoud J, Calvo IA, Olson N, Boukhali M, Steinlein OK, Roider E, Sattler EC, Huang D, Teh BT, Motamedi M, Haas W, Iliopoulos O. Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein. Nat Commun. 2017 06 28; 8:15866. PMID: 28656962; PMCID: PMC5493755.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  14. Okazaki A, Gameiro PA, Christodoulou D, Laviollette L, Schneider M, Chaves F, Stemmer-Rachamimov A, Yazinski SA, Lee R, Stephanopoulos G, Zou L, Iliopoulos O. Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers. J Clin Invest. 2017 May 01; 127(5):1631-1645. PMID: 28346230; PMCID: PMC5409089.
    Citations: 36     Fields:    Translation:HumansAnimals
  15. Salas-Vega S, Iliopoulos O, Mossialos E. Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines. JAMA Oncol. 2017 Mar 01; 3(3):382-390. PMID: 28033447.
    Citations: 31     Fields:    Translation:Humans
  16. Keibler MA, Wasylenko TM, Kelleher JK, Iliopoulos O, Vander Heiden MG, Stephanopoulos G. Metabolic requirements for cancer cell proliferation. Cancer Metab. 2016; 4:16. PMID: 27540483; PMCID: PMC4989334.
    Citations: 50     
  17. Noonan HR, Metelo AM, Kamei CN, Peterson RT, Drummond IA, Iliopoulos O. Loss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma. Dis Model Mech. 2016 08 01; 9(8):873-84. PMID: 27491085.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  18. Metelo AM, Noonan H, Iliopoulos O. HIF2a inhibitors for the treatment of VHL disease. Oncotarget. 2015 Sep 15; 6(27):23036-7. PMID: 26325097.
    Citations: 10     Fields:    Translation:HumansAnimals
  19. Black JC, Atabakhsh E, Kim J, Biette KM, Van Rechem C, Ladd B, Burrowes PD, Donado C, Mattoo H, Kleinstiver BP, Song B, Andriani G, Joung JK, Iliopoulos O, Montagna C, Pillai S, Getz G, Whetstine JR. Hypoxia drives transient site-specific copy gain and drug-resistant gene expression. Genes Dev. 2015 May 15; 29(10):1018-31. PMID: 25995187.
    Citations: 37     Fields:    Translation:HumansAnimalsCells
  20. Gbormittah FO, Bones J, Hincapie M, Tousi F, Hancock WS, Iliopoulos O. Clusterin glycopeptide variant characterization reveals significant site-specific glycan changes in the plasma of clear cell renal cell carcinoma. J Proteome Res. 2015 Jun 05; 14(6):2425-36. PMID: 25855029.
    Citations: 8     Fields:    Translation:Humans
  21. Metelo AM, Noonan HR, Li X, Jin Y, Baker R, Kamentsky L, Zhang Y, van Rooijen E, Shin J, Carpenter AE, Yeh JR, Peterson RT, Iliopoulos O. Pharmacological HIF2a inhibition improves VHL disease-associated phenotypes in zebrafish model. J Clin Invest. 2015 May; 125(5):1987-97. PMID: 25866969; PMCID: PMC4463187.
    Citations: 16     Fields:    Translation:HumansAnimals
  22. Gbormittah FO, Lee LY, Taylor K, Hancock WS, Iliopoulos O. Comparative studies of the proteome, glycoproteome, and N-glycome of clear cell renal cell carcinoma plasma before and after curative nephrectomy. J Proteome Res. 2014 Nov 07; 13(11):4889-900. PMID: 25184692.
    Citations: 10     Fields:    Translation:Humans
  23. Laviolette LA, Wilson J, Koller J, Neil C, Hulick P, Rejtar T, Karger B, Teh BT, Iliopoulos O. Human folliculin delays cell cycle progression through late S and G2/M-phases: effect of phosphorylation and tumor associated mutations. PLoS One. 2013; 8(7):e66775. PMID: 23874397.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  24. Gameiro PA, Laviolette LA, Kelleher JK, Iliopoulos O, Stephanopoulos G. Cofactor balance by nicotinamide nucleotide transhydrogenase (NNT) coordinates reductive carboxylation and glucose catabolism in the tricarboxylic acid (TCA) cycle. J Biol Chem. 2013 May 03; 288(18):12967-77. PMID: 23504317.
    Citations: 57     Fields:    Translation:AnimalsCells
  25. Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 2013 Mar 05; 17(3):372-85. PMID: 23473032.
    Citations: 156     Fields:    Translation:HumansAnimalsCells
  26. Nicolay BN, Gameiro PA, Tschöp K, Korenjak M, Heilmann AM, Asara JM, Stephanopoulos G, Iliopoulos O, Dyson NJ. Loss of RBF1 changes glutamine catabolism. Genes Dev. 2013 Jan 15; 27(2):182-96. PMID: 23322302.
    Citations: 58     Fields:    Translation:HumansAnimalsCells
  27. Tousi F, Bones J, Iliopoulos O, Hancock WS, Hincapie M. Multidimensional liquid chromatography platform for profiling alterations of clusterin N-glycosylation in the plasma of patients with renal cell carcinoma. J Chromatogr A. 2012 Sep 21; 1256:121-8. PMID: 22885037.
    Citations: 6     Fields:    Translation:HumansCells
  28. Scherber C, Aranyosi AJ, Kulemann B, Thayer SP, Toner M, Iliopoulos O, Irimia D. Epithelial cell guidance by self-generated EGF gradients. Integr Biol (Camb). 2012 Mar; 4(3):259-69. PMID: 22314635.
    Citations: 37     Fields:    Translation:HumansAnimalsCells
  29. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, Kelleher JK, Vander Heiden MG, Iliopoulos O, Stephanopoulos G. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2011 Nov 20; 481(7381):380-4. PMID: 22101433.
    Citations: 780     Fields:    Translation:HumansCells
  30. Heddleston JM, Wu Q, Rivera M, Minhas S, Lathia JD, Sloan AE, Iliopoulos O, Hjelmeland AB, Rich JN. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ. 2012 Mar; 19(3):428-39. PMID: 21836617.
    Citations: 63     Fields:    Translation:HumansCells
  31. Rafalko A, Iliopoulos O, Fusaro VA, Hancock W, Hincapie M. Immunoaffinity enrichment and liquid chromatography-selected reaction monitoring mass spectrometry for quantitation of carbonic anhydrase 12 in cultured renal carcinoma cells. Anal Chem. 2010 Nov 01; 82(21):8998-9005. PMID: 20936840.
    Citations: 4     Fields:    Translation:HumansCells
  32. Zimmer M, Lamb J, Ebert BL, Lynch M, Neil C, Schmidt E, Golub TR, Iliopoulos O. The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2. Cancer Res. 2010 Apr 15; 70(8):3071-9. PMID: 20354189; PMCID: PMC2861799.
    Citations: 19     Fields:    Translation:HumansCells
  33. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, Mostoslavsky R. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell. 2010 Jan 22; 140(2):280-93. PMID: 20141841; PMCID: PMC2821045.
    Citations: 465     Fields:    Translation:AnimalsCells
  34. Zimmer M, Ebert BL, Neil C, Brenner K, Papaioannou I, Melas A, Tolliday N, Lamb J, Pantopoulos K, Golub T, Iliopoulos O. Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Mol Cell. 2008 Dec 26; 32(6):838-48. PMID: 19111663; PMCID: PMC3978139.
    Citations: 94     Fields:    Translation:HumansCells
  35. Michaelson MD, Iliopoulos O, McDermott DF, McGovern FJ, Harisinghani MG, Oliva E. Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma. N Engl J Med. 2008 May 29; 358(22):2389-96. PMID: 18509125.
    Citations: 1     Fields:    Translation:Humans
  36. Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ. Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int. 2008 Aug; 102(3):358-63. PMID: 18394010; PMCID: PMC4112353.
    Citations: 13     Fields:    Translation:HumansCells
  37. Iliopoulos O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol. 2006 Dec 10; 24(35):5593-600. PMID: 17158545.
    Citations: 22     Fields:    Translation:HumansCells
  38. Iliopoulos O, Chan-Smutko G, Gonzalez RG, Louis DN, Stone JR. Case records of the Massachusetts General Hospital. Case 23-2006. A 36-year-old man with numbness in the left [corrected] hand and hypertension. N Engl J Med. 2006 Jul 27; 355(4):394-402. PMID: 16870919.
    Citations:    Fields:    Translation:Humans
  39. Mizukami Y, Jo WS, Duerr EM, Gala M, Li J, Zhang X, Zimmer MA, Iliopoulos O, Zukerberg LR, Kohgo Y, Lynch MP, Rueda BR, Chung DC. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med. 2005 Sep; 11(9):992-7. PMID: 16127434.
    Citations: 180     Fields:    Translation:HumansAnimalsCells
  40. Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6277S-81S. PMID: 15448017.
    Citations: 8     Fields:    Translation:Humans
  41. Skates S, Iliopoulos O. Molecular markers for early detection of renal carcinoma: investigative approach. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6296S-301S. PMID: 15448020.
    Citations: 3     Fields:    Translation:Humans
  42. Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O, Chung DC. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res. 2004 Mar 01; 64(5):1765-72. PMID: 14996738.
    Citations: 60     Fields:    Translation:HumansCells
  43. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res. 2004 Feb; 2(2):89-95. PMID: 14985465.
    Citations: 108     Fields:    Translation:HumansAnimalsCells
  44. Zimmer M, Iliopoulos O. Molecular genetics of kidney cancer. Cancer Treat Res. 2003; 116:3-27. PMID: 14650823.
    Citations: 2     Fields:    Translation:Humans
  45. Neumann HP, Hoegerle S, Manz T, Brenner K, Iliopoulos O. How many pathways to pheochromocytoma? Semin Nephrol. 2002 Mar; 22(2):89-99. PMID: 11891502.
    Citations: 2     Fields:    Translation:Humans
  46. Iliopoulos O. von Hippel-Lindau disease: genetic and clinical observations. Front Horm Res. 2001; 28:131-66. PMID: 11443850.
    Citations: 3     Fields:    Translation:Humans
  47. Iliopoulos O, Eng C. Genetic and clinical aspects of familial renal neoplasms. Semin Oncol. 2000 Apr; 27(2):138-49. PMID: 10768593.
    Citations: 8     Fields:    Translation:HumansAnimals
  48. Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG, Elledge SJ, Conaway RC, Harper JW, Conaway JW. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science. 1999 Apr 23; 284(5414):657-61. PMID: 10213691.
    Citations: 269     Fields:    Translation:AnimalsCells
  49. Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel RS. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res. 1998 Nov 01; 58(21):4957-62. PMID: 9810005.
    Citations: 22     Fields:    Translation:AnimalsCells
  50. Iliopoulos O, Ohh M, Kaelin WG. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A. 1998 Sep 29; 95(20):11661-6. PMID: 9751722; PMCID: PMC21697.
    Citations: 71     Fields:    Translation:HumansCells
  51. Kaelin WG, Iliopoulos O, Lonergan KM, Ohh M. Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med. 1998 Jun; 243(6):535-9. PMID: 9681855.
    Citations: 10     Fields:    Translation:Humans
  52. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG, Iliopoulos O. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell. 1998 Jun; 1(7):959-68. PMID: 9651579.
    Citations: 139     Fields:    Translation:HumansAnimalsCells
  53. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol. 1998 Feb; 18(2):732-41. PMID: 9447969.
    Citations: 125     Fields:    Translation:HumansCells
  54. Iliopoulos O, Kaelin WG. The molecular basis of von Hippel-Lindau disease. Mol Med. 1997 May; 3(5):289-93. PMID: 9205944; PMCID: PMC2230077.
    Citations: 10     Fields:    Translation:HumansCells
  55. Corless CL, Kibel AS, Iliopoulos O, Kaelin WG. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol. 1997 Apr; 28(4):459-64. PMID: 9104946.
    Citations: 27     Fields:    Translation:HumansCells
  56. Levy AP, Levy NS, Iliopoulos O, Jiang C, Kaplin WG, Goldberg MA. Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney Int. 1997 Feb; 51(2):575-8. PMID: 9027742.
    Citations: 19     Fields:    Translation:HumansCells
  57. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A. 1996 Oct 01; 93(20):10595-9. PMID: 8855223; PMCID: PMC38198.
    Citations: 233     Fields:    Translation:HumansCells
  58. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science. 1995 Sep 08; 269(5229):1444-6. PMID: 7660130.
    Citations: 201     Fields:    Translation:HumansAnimalsCells
  59. Iliopoulos O, Kibel A, Gray S, Kaelin WG. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med. 1995 Aug; 1(8):822-6. PMID: 7585187.
    Citations: 219     Fields:    Translation:HumansCells
  60. Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD. Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs. Am J Kidney Dis. 1992 Sep; 20(3):281-5. PMID: 1519610.
    Citations: 4     Fields:    Translation:Humans
  61. Iliopoulos O, Baroody FM, Naclerio RM, Bochner BS, Kagey-Sobotka A, Lichtenstein LM. Histamine-containing cells obtained from the nose hours after antigen challenge have functional and phenotypic characteristics of basophils. J Immunol. 1992 Apr 01; 148(7):2223-8. PMID: 1372025.
    Citations: 11     Fields:    Translation:HumansCells
  62. Iliopoulos O, Proud D, Adkinson NF, Creticos PS, Norman PS, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol. 1991 Apr; 87(4):855-66. PMID: 2013680.
    Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
  63. Iliopoulos O, Proud D, Adkinson NF, Norman PS, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Relationship between the early, late, and rechallenge reaction to nasal challenge with antigen: observations on the role of inflammatory mediators and cells. J Allergy Clin Immunol. 1990 Dec; 86(6 Pt 1):851-61. PMID: 2262642.
    Citations: 4     Fields:    Translation:Humans
  64. Charlesworth EN, Iliopoulos O, MacDonald SM, Kagey-Sobotka A, Lichtenstein LM. Cells and secretagogues involved in the human late-phase response. Int Arch Allergy Appl Immunol. 1989; 88(1-2):50-3. PMID: 2468620.
    Citations: 4     Fields:    Translation:HumansCells
  65. Iliopoulos O, Proud D, Norman PS, Lichtenstein LM, Kagey-Sobotka A, Naclerio RM. Nasal challenge with cold, dry air induces a late-phase reaction. Am Rev Respir Dis. 1988 Aug; 138(2):400-5. PMID: 2461672.
    Citations:    Fields:    Translation:Humans
  66. Togias A, Naclerio RM, Proud D, Pipkorn U, Bascom R, Iliopoulos O, Kagey-Sobotka A, Norman PS, Lichtenstein LM. Studies on the allergic and nonallergic nasal inflammation. J Allergy Clin Immunol. 1988 May; 81(5 Pt 1):782-90. PMID: 3286718.
    Citations: 13     Fields:    Translation:HumansPHPublic Health
  67. Naclerio RM, Kagey-Sobotka A, Lichtenstein LM, Togias AG, Iliopoulos O, Pipkorn U, Bascom R, Norman PS, Proud D. Observations on nasal late phase reactions. Immunol Invest. 1987-1988 Dec; 16(8):649-85. PMID: 3330982.
    Citations:    Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Iliopoulos's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (403)
Explore
_
Co-Authors (62)
Explore
_
Similar People (59)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.